Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'
Nat Commun
.
2018 Jul 26;9(1):2922.
doi: 10.1038/s41467-018-05048-0.
Authors
Nicolas Jacquelot
1
2
3
,
Laurence Zitvogel
4
5
6
7
,
Alexander M Eggermont
2
Affiliations
1
INSERM U1015, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.
2
Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805, Villejuif, France.
3
Division of Molecular Immunology, The Walter and Eliza Hall Institute of Medical Research, 3052, Parkville, Victoria, Australia.
4
INSERM U1015, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France. laurence.zitvogel@orange.fr.
5
Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805, Villejuif, France. laurence.zitvogel@orange.fr.
6
Faculté de Médecine - Université Paris-Saclay, Kremlin Bicêtre, 94276, France. laurence.zitvogel@orange.fr.
7
CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94805, France. laurence.zitvogel@orange.fr.
PMID:
30050125
PMCID:
PMC6062500
DOI:
10.1038/s41467-018-05048-0
No abstract available
Publication types
Letter
Comment
MeSH terms
B7-H1 Antigen*
Humans
Immunotherapy*
Melanoma
Programmed Cell Death 1 Receptor
T-Lymphocytes
Substances
B7-H1 Antigen
Programmed Cell Death 1 Receptor